As part of its business strategy, FORUM Pharmaceuticals selectively forges partnerships to strengthen its pipeline as well as to accelerate and augment its development and commercialization efforts in certain geographies and indications.
Current partnerships include:
Alpha-7 (α7) Agonist Program - FORUM Pharmaceuticals has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, encenicline, in Japan and several other Asian countries.
The Dominantly Inherited Alzheimer Network (DIAN) is an international research partnership of leading scientists determined to understand a rare form of Alzheimer’s disease caused by a gene mutation. Understanding this form of Alzheimer’s disease may provide clues to decoding other dementias and developing dementia treatments. FORUM Pharmaceuticals is a member of the DIAN Pharma Consortium, a partnership of pharmaceutical companies collaborating with DIAN to add industry expertise to the design and implementation of DIAN drug trials.
For more information about potential partnership opportunities, please contact: email@example.com.